Site menu

Search by ticker code:
Generic filters


Search by ticker code:
Generic filters

Search by ticker code:
Generic filters

Pro Medicus (ASX:PME) share price in focus on 2023 AGM

The Pro Medicus Ltd (ASX: PME) share price is currently higher after the company held its AGM.

Pro Medicus provides a full range of medical imaging software and services to hospitals, imaging centres and healthcare groups around the world.


The company’s cash and ‘other financial assets’ continues to grow, which enable the business to invest in developing its product suite, including AI, paying its dividends and take advantage of acquisition opportunities.

Pro Medicus said that while no acquisitions to date have met its criteria, the current circumstances surrounding the technology sector has meant the board is “starting to see valuations coming down such that an increasing number of opportunities may meet” its criteria in the future.

Dividend policy

In FY23 it grew its annual dividend by 36% to 30 cents per share, representing a dividend payout ratio of approximately 50%. The dividend was funded from the company’s internally generated cash flow.

Pro Medicus’ board expects that future dividends will continue to be fully franked.

The board will determine the appropriate level of dividends by looking at the “profitability of the business, its need for ongoing investment and the necessity to retain sufficient funds to pursue other growth opportunities.”

Growth plans

Pro Medicus said it has a plan for strong growth between FY24 to FY26.

The board and management have set “aggressive” growth targets in keeping with the company’s current and potential opportunities. It said it’s in the process of progressively implementing its plans to achieve the next growth phase.

Final thoughts on the Pro Medicus share price

Pro Medicus is probably the best business on the ASX. It has enormous profit margins, it’s growing and compounding at a fast pace, the dividend growth and balance sheet are excellent, and management seem extremely capable. And it keeps winning new contracts.

However, it’s priced for its excellence with an incredibly high price/earnings ratio (p/e ratio). Despite all of the interest rate hikes, the p/e ratio has increased over time.

It seems too expensive to buy shares today, but I’ve said that quite a few times over the years and now look where it is! If I were a shareholder, I’d be very pleased by what I’m seeing, including with this update.

$50,000 per year in passive income from shares? Yes, please!

With interest rates UP, now could be one of the best times to start earning passive income from a portfolio. Imagine earning 4%, 5% — or more — in dividend passive income from the best shares, LICs, or ETFs… it’s like magic.

So how do the best investors do it?

Chief Investment Officer Owen Rask has just released his brand new passive income report. Owen has outlined 10 of his favourite ETFs and shares to watch, his rules for passive income investing, why he would buy ETFs before LICs and more.

You can INSTANTLY access Owen’s report for FREE by CLICKING HERE NOW and creating a 100% FREE Rask Account.

(Psst. By creating a free Rask account, you’ll also get access to 15+ online courses, 1,000+ podcasts, invites to events, a weekly value investing newsletter and more!)

Unsubscribe anytime. Read our TermsFinancial Services GuidePrivacy Policy. We’ll never sell your email address. Our company is Australian owned.

Information warning: The information on this website is published by The Rask Group Pty Ltd (ABN: 36 622 810 995) is limited to factual information or (at most) general financial advice only. That means, the information and advice does not take into account your objectives, financial situation or needs. It is not specific to you, your needs, goals or objectives. Because of that, you should consider if the advice is appropriate to you and your needs, before acting on the information. If you don’t know what your needs are, you should consult a trusted and licensed financial adviser who can provide you with personal financial product advice. In addition, you should obtain and read the product disclosure statement (PDS) before making a decision to acquire a financial product. Please read our Terms and Conditions and Financial Services Guide before using this website. The Rask Group Pty Ltd is a Corporate Authorised Representative (#1280930) of AFSL #383169.

At the time of publishing, Jaz does not have a financial or commercial interest in any of the companies mentioned.
Skip to content